Truveta Leverages CDC, AI, and RWE Studies to Deepen Role in Health Data Analytics

Truveta delivered a data-rich week highlighted by multiple research updates that underscore its role in real-world evidence and AI-driven health analytics. A CDC-led study using Truveta Data analyzed more than 4 million antihypertensive prescriptions and found patients seen later in the day were less likely to fill and adhere to their medications over 90 days, suggesting operational factors influence outcomes.

This collaboration with the CDC showcases the scale and clinical depth of Truveta’s dataset, reinforcing its value to health systems and public health agencies. The company also spotlighted research using a fine-tuned GPT-4o model on its clinical data to predict early-onset colorectal cancer, reporting 73% sensitivity and 91% specificity and outperforming traditional machine-learning methods.

By analyzing conditions, labs, and clinical observations up to six months before diagnosis, the AI work positions Truveta as an emerging player in oncology risk stratification and preventive care analytics. In parallel, Truveta Research released updated GLP-1 monitoring findings showing GLP-1 drugs accounted for nearly 8% of all prescriptions in March 2026, the largest quarter-over-quarter increase since 2019, with first-time anti-obesity prescribing up 21.7%.

First-time semaglutide use rose more than 50%, likely aided by approval of the Wegovy pill, highlighting a fast-growing therapeutic category of high interest to manufacturers and payers. Separate Truveta Research data featured in USA TODAY showed estrogen-based hormone replacement therapy prescriptions more than doubled from 2018 to 2026, with strong growth in patch-based therapies contributing to supply constraints.

These HRT and GLP-1 trend insights underscore rising demand for real-world data to inform access, policy, and commercial decisions. Truveta also noted that its data has supported four recent urology-focused studies spanning medical therapy, oncology, and men’s health, emphasizing the platform’s role in capturing long-term outcomes beyond traditional clinical trials.

Across public health, oncology, metabolic disease, and urology, the week’s developments highlight broadening adoption of Truveta’s data assets for outcomes research and AI applications. While no financial metrics were disclosed, the expanding breadth of use cases and high-profile research collaborations point to strengthening strategic relevance in the real-world evidence and health analytics market.